Czechia· CZ-0268094
ZOKINVY
A lonafarnib product containing lonafarnib, registered in Czechia by Integral Pharma Solutions EU Limited, Dublin. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Lonafarnib is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX20 (lonafarnib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Lonafarnib · ATC A16AX20
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- LONAFARNIB
- Manufacturer
- Integral Pharma Solutions EU Limited, Dublin
- Country
- Czechia (CZ)
- ATC code
- A16AX20
- ATC class
- Lonafarnib
- Defined daily dose
- 0.275 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
303 interactions on record for lonafarnib.
Graded by severity as the source publishes them — 153 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lonafarnib · interactions on record
303 records
- 153 severe
- 145 moderate
- 5 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- CimetidineA02BA01severe
- CisaprideA03FA02severe
- AprepitantA04AD12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lonafarnib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZokinvy 75 mgTMC Pharma (EU)
- FinlandZokinvyIntegral Pharma Solutions EU Limited
- FranceZOKINVY 75 mg, géluleTMC PHARMA (EU) (IRLANDE)
- IrelandZokinvy 75 mg hard capsulesTMC Pharma (EU) Limited
- IcelandZokinvyTMC Pharma (EU) Limited
- NetherlandsZokinvy 75mg, harde capsulesTMC Pharma (EU) Limited
- PolandZokinvyTMC Pharma (EU) Ltd.
- SwedenZokinvy 75 mg Kapsel, hårdTMC Pharma (EU) Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- France · Zokinvy
- Iceland · Zokinvy
- Liechtenstein · Zokinvy
- Norway · Zokinvy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/33e5b333-d1b6-428e-b702-eec15aa6ad6a GET /v1/drugs/33e5b333-d1b6-428e-b702-eec15aa6ad6a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "CPS DUR",
"source": "sukl",
"strength": "75MG",
"pack_size": "30",
"substance": "LONAFARNIB",
"cz_kod_sukl": "0268094",
"product_type": "CH",
"substance_codes": "16641",
"registration_state": "R",
"registration_number": "EU/1/22/1660/002"
}See everything about lonafarnib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.